| Phase 2 studies showed that the dosing regimen for fepixnebart (LY3016859), a new drug being developed to treat various types of chronic pain, was effective in engaging its target, with a high percentage of subjects showing strong engagement. |
| Epiregulin, a ligand for EGFR, is a promising target for treating chronic pain due to its role in persistent EGFR pathway activation. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.